CMS Rule Levels Playing Field for Tiny, Battery-Free Bladder Control Implant

SAN JOSE, CA – July 08, 2026 – In a move that could reshape the billion-dollar market for urinary incontinence treatments, federal regulators have proposed a rule that puts a disruptive new technology on equal footing with long-established industry giants. The Centers for Medicare & Medicaid Services (CMS) has announced its intention to provide the same payment level for Neuspera Medical’s tiny, externally powered sacral neuromodulation (SNM) system as it does for the bulky, battery-powered devices that have dominated the field for decades.

This decision is more than a bureaucratic line item; it’s a powerful signal that innovation focused on patient experience and long-term cost reduction is being recognized and rewarded. For the millions of people who suffer from urinary urge incontinence (UUI) but have been hesitant to undergo implantation of a device often compared to the size of an Oreo cookie, this development opens a significant new door.

A Landmark Decision for Access and Innovation

The proposed Calendar Year 2027 Outpatient Prospective Payment System (OPPS) Rule assigns Neuspera's Integrated Sacral Neuromodulation (iSNM) system to Ambulatory Payment Classification (APC) 5464. This move grants the novel device payment parity with legacy systems from market leaders Medtronic and Boston Scientific. Furthermore, the rule proposes a substantial 11.8% increase in the payment rate for this category to $22,150, a figure that far outpaces the general 2.4% rate increase across the system. This suggests CMS sees significant value in ensuring access to these therapies.

Combined with last year’s decision to add the iSNM billing code to Medicare's existing National Coverage Determination for sacral nerve stimulation, the financial and administrative pathways for adoption are now significantly streamlined. For Neuspera, a smaller company challenging a market of entrenched players, this is a critical victory.

"We commend CMS for their thorough review and for making the decision to assign APC Level 4 to the Neuspera sacral neuromodulation system, with a strong proposed payment increase," said David Van Meter, CEO of Neuspera. "This puts us on equal footing and will allow many more patients to benefit from SNM without the complications of implanted batteries commonly associated with legacy systems." Van Meter also alluded to the competitive struggle, noting, "A testament to the importance of our therapy is the opposition it faced from those invested in the status quo. Ultimately, what is best for patients prevailed."

Redefining the Patient Experience

Despite the high clinical efficacy of SNM therapy, with 80-90% of patients seeing improvement, the market remains drastically underpenetrated. Fewer than five in one hundred potential candidates currently opt for the treatment. A major reason for this reluctance is the device itself.

Traditional SNM systems require surgeons to create a pocket in the buttock tissue to house a metal, battery-powered implantable pulse generator (IPG). A newly published Cleveland Clinic study puts hard numbers to the anecdotal complaints: 62% of patients can feel the device, 36% experience activity-related discomfort, and 18% report that the implant limits their sleep or movement. Beyond discomfort, these implanted batteries carry risks of infection and require replacement surgeries every several years, adding cost, risk, and inconvenience over a patient's lifetime. Revisions and replacements currently account for up to 30% of all SNM procedures, costing the U.S. healthcare system over $300 million annually.

Neuspera’s iSNM system, which received FDA approval in June 2025, was engineered to eliminate these problems. The implant itself is minuscule and contains no battery. It is powered wirelessly by a small, external transmitter worn by the patient as needed. This design eradicates the need for a surgical pocket and the associated pain, discomfort, and risk of complications.

"Neuspera's externally powered iSNM system is a major step forward that I'm excited to have in my armamentarium," commented Dr. Charles R. Powell, Professor of Urology at Indiana University. "For the many patients struggling with complications from implanted batteries, including pocket pain, infections, and repeated replacement surgeries, this finally solves those long-standing problems. Equally important, it offers an attractive option to the much larger number of patients who have avoided sacral neuromodulation because they simply don't want a bulky device implanted in their body."

A Catalyst for Competition in a Stagnant Market

The CMS decision is poised to be a major disruptive force. By neutralizing the reimbursement variable, it forces competition to shift from established contracts and market power to clinical and patient-centered value. The innovator from San Jose can now compete directly on the merits of its technology: a less invasive procedure, improved patient comfort, and the elimination of costly and painful battery replacement surgeries.

This creates a compelling value proposition not just for patients, but for the entire healthcare system. By potentially reducing the 30% of procedures dedicated to revisions and replacements, the iSNM system could generate significant long-term cost savings, a key consideration for both private payers and government programs like Medicare.

The proposed rule, which is open for public comment until the end of August, represents a victory for a patient-centric approach to medical technology. While incumbents may have argued for maintaining a distinction based on their devices' longer track record, CMS appears to have been persuaded by the potential benefits of a fundamentally different and less burdensome technology platform.

To back its claims with data, Neuspera is accelerating its FREEDOM registry, a study designed to capture real-world evidence on quality of life, pain relief, and patient satisfaction, with a particular focus on individuals switching from traditional SNM systems. This includes a growing cohort of patients whose implants have become problematic after significant weight loss, a side effect of the popular new GLP-1 drugs. By systematically collecting the "voice of the patient," the company is building the evidence base needed to guide adoption and prove its long-term value proposition. This strategy—combining breakthrough technology with robust, real-world data collection—is a model for how modern medical innovators can drive meaningful change in established systems.